Interpretation of 2023 AHA Scientific Statement:Cancer Therapy Related Hypertension
10.3870/j.issn.1004-0781.2024.02.002
- VernacularTitle:2023美国心脏协会癌症治疗相关高血压科学声明解读
- Author:
Lizhu HAN
1
;
Qinan YIN
;
Yuan BIAN
;
Ziyan LYU
;
Xuefei HUANG
;
Yang LEI
;
Min CHEN
Author Information
1. 四川省医学科学院·四川省人民医院/电子科技大学附属医院药学部·个体化药物治疗四川省重点实验室,成都 610072
- Keywords:
Antihypertensive drugs;
Cancer therapy;
Hypertension
- From:
Herald of Medicine
2024;43(2):155-160
- CountryChina
- Language:Chinese
-
Abstract:
In January 2023,the American Heart Association(AHA)released A Scientific Statement:Cancer Therapy Related Hypertension,provided an overview of the mechanisms and clinical management of anticancer therapy related hypertension.Contemporary anticancer drugs are mostly at the expense of cardiovascular toxicities,one of the most common side effects is hypertension,especially vascular endothelial growth factor inhibitors,as well as tyrosine kinase inhibitors and proteasome inhibitors.Cancer therapy related hypertension is often dose limiting,and is usually reversible after interruption or discontinuation of treatment.The exact molecular mechanisms underlying hypertension are unclear,recent discoveries indicate an important role for decreased nitric oxide,increased endothelin-1,endothelial dysfunction,increased sympathetic outflow,and microvascular rarefaction.Based on the International Cardio Oncology Society(IC-OS),this article provides an interpretation of the diagnosis and management of hypertension related to cancer treatment.Insufficient evidence exists supporting an antihypertensive medication strategy specific to patients with anticancer therapy induced hypertension,therefore,antihypertensive management should follow current guidelines for the general population..Multidisciplinary cooperation is needed to optimize management to ensure the optimal therapeutic effect from cancer treatment while minimizing competing cardiovascular toxicities.
